SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status

KRAS is the most commonly mutated oncogene. Targeted therapies have been developed against mediators of key downstream signaling pathways, predominantly components of the RAF/MEK/ERK kinase cascade. Unfortunately, single-agent efficacy of these agents is limited both by intrinsic and acquired resistance. Survival of drug-tolerant persister cells (DTPs) within the heterogeneous tumor population and/or acquired mutations that reactivate receptor tyrosine kinase (RTK)/RAS signaling can lead to outgrowth of tumor initiating cells (TICs) and drive therapeutic resistance. Here, we show that targeting the key RTK/RAS pathway signaling intermediates SOS1 or KSR1 both enhances the efficacy of, and prevents resistance to, the MEK inhibitor trametinib in KRAS-mutated lung (LUAD) and colorectal (COAD) adenocarcinoma cell lines depending on the specific mutational landscape. The SOS1 inhibitor BI-3406 enhanced the efficacy of trametinib and prevented trametinib resistance by targeting spheroid initiating cells (SICs) in KRASG12/G13-mutated LUAD and COAD cell lines that lacked PIK3CA co-mutations. Cell lines with KRASQ61 and/or PIK3CA mutations were insensitive to trametinib and BI-3406 combination therapy. In contrast, deletion of the RAF/MEK/ERK scaffold protein KSR1 prevented drug-induced SIC upregulation and restored trametinib sensitivity across all tested KRAS mutant cell lines in both PIK3CA- mutated and PIK3CA wildtype cancers. Our findings demonstrate that vertical inhibition of RTK/RAS signaling is an effective strategy to prevent therapeutic resistance in KRAS- mutated cancers, but therapeutic efficacy is dependent on both the specific KRAS mutant and underlying co-mutations. Thus, selection of optimal therapeutic combinations in KRAS-mutated cancers will require a detailed understanding of functional dependencies imposed by allele-specific KRAS mutations. Significance Statement We provide an experimental framework for evaluating both adaptive and acquired resistance to RAS pathway-targeted therapies and demonstrate how targeting specific RAS pathway signaling intermediates SOS1 or KSR1 enhanced effectiveness of and prevented resistance to MEK inhibitors in KRAS-mutated cancer cells with genotypic precision. The contribution of either effector was dependent upon the mutational landscape: SOS1 inhibition synergized with trametinib in KRASG12/G13-mutated cells expressing WT PI3K but not in KRASQ61-mutated cells or if PIK3CA is mutated. KSR1 deletion inhibited MEK/ERK complex stability and was effective in cells that are unresponsive to SOS1 inhibition. These data demonstrate how a detailed understanding of functional dependencies imposed both by allele specific KRAS mutations and specific co-mutations facilitates the optimization of therapeutic combinations.

[1]  R. Kortum,et al.  In situ modeling of acquired resistance to RTK/RAS pathway targeted therapies , 2023, bioRxiv.

[2]  M. Ladanyi,et al.  MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression , 2022, npj Precision Oncology.

[3]  R. Kortum,et al.  Heterogeneity in RAS mutations: One size does not fit all , 2022, Science Signaling.

[4]  E. Petricoin,et al.  Functional and biological heterogeneity of KRASQ61 mutations , 2022, Science Signaling.

[5]  J. Mazières,et al.  Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer , 2022, Cancers.

[6]  T. Pons,et al.  KSR induces RAS‐independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors , 2022, Molecular oncology.

[7]  G. Kroemer,et al.  Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges , 2021, Molecular cancer.

[8]  Fang Wu,et al.  The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer , 2021, Frontiers in Oncology.

[9]  Anna M. Schmoker,et al.  Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation , 2021, Proceedings of the National Academy of Sciences.

[10]  M. Tsao,et al.  Mechanism of drug tolerant persister cancer cells: The landscape and clinical implication for therapy. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  B. Garcia,et al.  Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting , 2021, Nature Communications.

[12]  D. Carbone,et al.  Targeting KRAS in non-small cell lung cancer: recent progress and new approaches. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Hata,et al.  Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer , 2021, Cancers.

[14]  R. Kortum,et al.  Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS. , 2021, Journal of medicinal chemistry.

[15]  N. Kraut,et al.  Targeting Son of Sevenless 1: The pacemaker of KRAS. , 2021, Current opinion in chemical biology.

[16]  P. Ettmayer,et al.  One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS. , 2021, Journal of medicinal chemistry.

[17]  Robert E. Lewis,et al.  KSR1- and ERK-dependent translational regulation of the epithelial-to-mesenchymal transition , 2021, bioRxiv.

[18]  Zhentao Yang,et al.  Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Anti-Tumor T-cell Immunity. , 2020, Cancer discovery.

[19]  S. Y. Kim,et al.  Update 2020: Management of Non-Small Cell Lung Cancer , 2020, Lung.

[20]  William M. Marsiglia,et al.  Structural basis for the action of the drug trametinib at KSR-bound MEK , 2020, Nature.

[21]  Mary E. Duffy,et al.  Structural basis for the action of the drug trametinib at KSR-bound MEK , 2020, Nature.

[22]  R. Kortum,et al.  Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer , 2020, eLife.

[23]  P. Ettmayer,et al.  BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. , 2020, Cancer discovery.

[24]  M. McMahon,et al.  Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. , 2020, Cell reports.

[25]  A. Adjei,et al.  KRAS: From undruggable to a druggable Cancer Target. , 2020, Cancer treatment reviews.

[26]  Laura E. Herring,et al.  Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers , 2020, Cell reports.

[27]  G. Tortora,et al.  Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives , 2020, Cancers.

[28]  J. Hartley,et al.  The Frequency of Ras Mutations in Cancer , 2020, Cancer Research.

[29]  A. Hata,et al.  Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights. , 2020, Pharmacology & therapeutics.

[30]  Davide Risso,et al.  Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition , 2020, Nature.

[31]  Henry W. Long,et al.  Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. , 2020, Cancer cell.

[32]  Hiromasa Yamamoto,et al.  YES1 activation induces acquired resistance to neratinib in HER2‐amplified breast and lung cancers , 2019, Cancer Science.

[33]  D. Esposito,et al.  Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling. , 2019, Molecular cell.

[34]  F. Fece de la Cruz,et al.  Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition , 2019, Clinical Cancer Research.

[35]  J. Fernandez-Banet,et al.  The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. , 2019, Cancer discovery.

[36]  R. Doebele Acquired Resistance Is Oncogene and Drug Agnostic. , 2019, Cancer cell.

[37]  Joshua M. Dempster,et al.  Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. , 2019, Cell reports.

[38]  N. Haginoya,et al.  DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model , 2019, Oncotarget.

[39]  J. Ahn,et al.  Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer , 2019, Investigational New Drugs.

[40]  M. Ebert,et al.  MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer , 2019, Nature Communications.

[41]  R. Kortum,et al.  Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in RAS-mutant cancer cells , 2019, Small GTPases.

[42]  Donghwa Kim,et al.  AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells , 2019, Cell Death & Disease.

[43]  R. Rosell,et al.  Cancer Stem Cell Biomarkers in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer. , 2019, Clinical lung cancer.

[44]  H. Briem,et al.  Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction , 2019, Proceedings of the National Academy of Sciences.

[45]  Yue Yu,et al.  EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency , 2019, Clinical Cancer Research.

[46]  S. Yano,et al.  AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells , 2019, Nature Communications.

[47]  G. Vassalli Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells , 2019, Stem cells international.

[48]  R. Sachidanandam,et al.  SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors , 2019, Cell reports.

[49]  J. Kinney,et al.  A Transcription Factor Addiction in Leukemia Imposed by the MLL Promoter Sequence. , 2018, Cancer cell.

[50]  J. Soh,et al.  Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells , 2018, Molecular Cancer Research.

[51]  Dong-Wan Kim,et al.  Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[52]  D. Morrison,et al.  Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation , 2018, Science Signaling.

[53]  Channing J Der,et al.  KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. , 2018, Cold Spring Harbor perspectives in medicine.

[54]  B. Neel,et al.  SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. , 2018, Cancer discovery.

[55]  Krister Wennerberg,et al.  PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells , 2018, Science Translational Medicine.

[56]  G. Kiss,et al.  RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers , 2018, Nature Cell Biology.

[57]  T. Salame,et al.  A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways , 2018, Clinical Cancer Research.

[58]  R. Bernards,et al.  SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo , 2018, Nature Medicine.

[59]  J. Soh,et al.  Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations , 2018, Cancer science.

[60]  Ken Chen,et al.  Systematic Functional Annotation of Somatic Mutations in Cancer. , 2018, Cancer cell.

[61]  P. Zarrinkar,et al.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.

[62]  T. Salame,et al.  An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors , 2017, EMBO molecular medicine.

[63]  M. Tiseo,et al.  Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines , 2017, Journal of experimental & clinical cancer research : CR.

[64]  T. Bivona,et al.  Understanding and targeting resistance mechanisms in NSCLC , 2017, Nature Reviews Cancer.

[65]  H. Clevers,et al.  Cancer stem cells revisited , 2017, Nature Medicine.

[66]  K. O'Byrne,et al.  Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC , 2017, Oncotarget.

[67]  Lorin Crawford,et al.  A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. , 2017, Cell reports.

[68]  A. Jimeno,et al.  EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases. , 2017, Cancer research.

[69]  M. Varella‐Garcia,et al.  Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling , 2017, Molecular Cancer Therapeutics.

[70]  R. Weinberg,et al.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.

[71]  Ying Tang,et al.  Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency , 2017, Science Translational Medicine.

[72]  S. Haan,et al.  Tumor-Initiating Cells: a criTICal review of isolation approaches and new challenges in targeting strategies , 2017, Molecular Cancer.

[73]  L. Qu,et al.  At the crossroads of cancer stem cells and targeted therapy resistance. , 2017, Cancer letters.

[74]  R. Salgia,et al.  Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. , 2016, Cancer letters.

[75]  A. Dar,et al.  Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling , 2016, Nature.

[76]  J. Grilley-Olson,et al.  A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors , 2016, Investigational New Drugs.

[77]  Peter K. Sorger,et al.  Conservation of protein abundance patterns reveals the regulatory architecture of the EGFR-MAPK pathway , 2016, Science Signaling.

[78]  Robert E. Lewis,et al.  KSR1 and EPHB4 Regulate Myc and PGC1β To Promote Survival of Human Colon Tumors , 2016, Molecular and Cellular Biology.

[79]  C. Rudin,et al.  A combinatorial strategy for treating KRAS mutant lung cancer , 2016, Nature.

[80]  Jae Cheol Lee,et al.  Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer , 2016, Oncotarget.

[81]  E. Petricoin,et al.  Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. , 2016, Cancer cell.

[82]  M. Nowak,et al.  Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers , 2015, Nature Communications.

[83]  Robert E. Lewis,et al.  AMPK Promotes Aberrant PGC1β Expression To Support Human Colon Tumor Cell Survival , 2015, Molecular and Cellular Biology.

[84]  S. Asthana,et al.  RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer , 2015, Nature Medicine.

[85]  Sourav Bandyopadhyay,et al.  Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions. , 2015, Cancer research.

[86]  W. Pao,et al.  Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. , 2015, Cancer research.

[87]  John C. Hunter,et al.  Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations , 2015, Molecular Cancer Research.

[88]  P. Jänne,et al.  Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer. , 2015, Cancer discovery.

[89]  Kevin Struhl,et al.  Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation , 2015, Proceedings of the National Academy of Sciences.

[90]  Frank McCormick,et al.  KRAS as a Therapeutic Target , 2015, Clinical Cancer Research.

[91]  J. Meller,et al.  Combined Rational Design and a High Throughput Screening Platform for Identifying Chemical Inhibitors of a Ras-activating Enzyme* , 2015, The Journal of Biological Chemistry.

[92]  Parantu K. Shah,et al.  Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. , 2015, Cancer research.

[93]  Emmanuel C. Alozie,et al.  Promises and Challenges , 2015 .

[94]  T. Bekaii-Saab,et al.  Selumetinib for the treatment of cancer , 2015, Expert opinion on investigational drugs.

[95]  Yi Zheng,et al.  Rational design of small molecule inhibitors targeting the Ras GEF, SOS1. , 2014, Chemistry & biology.

[96]  M. Cristofanilli,et al.  Cancer stem cells: implications for cancer therapy. , 2014, Oncology.

[97]  P. Poulikakos,et al.  Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.

[98]  J. Rodríguez-Fernández,et al.  A Novel MEK-ERK-AMPK Signaling Axis Controls Chemokine Receptor CCR7-dependent Survival in Human Mature Dendritic Cells* , 2014, The Journal of Biological Chemistry.

[99]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[100]  D. Carbone,et al.  EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling. , 2014, Cancer research.

[101]  R. Bernards,et al.  RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. , 2014, Cell reports.

[102]  John D. Minna,et al.  Essential Role of Aldehyde Dehydrogenase 1A3 for the Maintenance of Non–Small Cell Lung Cancer Stem Cells Is Associated with the STAT3 Pathway , 2014, Clinical Cancer Research.

[103]  D. Raha,et al.  The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. , 2014, Cancer research.

[104]  Andreas Schlicker,et al.  Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. , 2014, Cell reports.

[105]  P. Bunn,et al.  Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer , 2013, PloS one.

[106]  Alexey I. Nesvizhskii,et al.  Reconstructing targetable pathways in lung cancer by integrating diverse omics data , 2013, Nature Communications.

[107]  P. L. McCormack,et al.  Trametinib: First Global Approval , 2013, Drugs.

[108]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[109]  Mitsuhiko Ikura,et al.  NMR-based functional profiling of RASopathies and oncogenic RAS mutations , 2013, Proceedings of the National Academy of Sciences.

[110]  Chin-Lee Wu,et al.  Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[111]  Carlotta Costa,et al.  MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. , 2012, Cancer research.

[112]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[113]  Min Yu,et al.  TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers , 2012, Cell.

[114]  Robert E. Lewis,et al.  Kinase Suppressor of Ras 1 (KSR1) Regulates PGC1α and Estrogen-Related Receptor α To Promote Oncogenic Ras-Dependent Anchorage-Independent Growth , 2011, Molecular and Cellular Biology.

[115]  Marian Kelley,et al.  One size does not fit all. , 2011, Bioanalysis.

[116]  Laura A. Sullivan,et al.  Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. , 2010, Cancer research.

[117]  Robert E. Lewis,et al.  KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. , 2009, Cell metabolism.

[118]  William Pao,et al.  Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer , 2009, Proceedings of the National Academy of Sciences.

[119]  G. Smyth,et al.  ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. , 2009, Journal of immunological methods.

[120]  Deborah K. Morrison,et al.  Signaling dynamics of the KSR1 scaffold complex , 2009, Proceedings of the National Academy of Sciences.

[121]  Patricia Greninger,et al.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.

[122]  Sridhar Ramaswamy,et al.  Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.

[123]  Feng Jiang,et al.  Aldehyde Dehydrogenase 1 Is a Tumor Stem Cell-Associated Marker in Lung Cancer , 2009, Molecular Cancer Research.

[124]  Jun Wang,et al.  Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells , 2006, Cancer biology & therapy.

[125]  Robert E. Lewis,et al.  The Molecular Scaffold Kinase Suppressor of Ras 1 Is a Modifier of RasV12-Induced and Replicative Senescence , 2006, Molecular and Cellular Biology.

[126]  Hiroshi Sakaue,et al.  The Molecular Scaffold Kinase Suppressor of Ras 1 (KSR1) Regulates Adipogenesis , 2005, Molecular and Cellular Biology.

[127]  Robert E. Lewis,et al.  The Molecular Scaffold KSR1 Regulates the Proliferative and Oncogenic Potential of Cells , 2004, Molecular and Cellular Biology.

[128]  R. Kolesnick,et al.  Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice. , 2003, Cancer research.

[129]  Kenneth M. Murphy,et al.  Kinase Suppressor of Ras (KSR) Is a Scaffold Which Facilitates Mitogen-Activated Protein Kinase Activation In Vivo , 2002, Molecular and Cellular Biology.

[130]  R. Klemke,et al.  Four Human Ras Homologs Differ in Their Abilities to Activate Raf-1, Induce Transformation, and Stimulate Cell Motility* , 1999, The Journal of Biological Chemistry.

[131]  G. Rubin,et al.  Identification of Constitutive and Ras-Inducible Phosphorylation Sites of KSR: Implications for 14-3-3 Binding, Mitogen-Activated Protein Kinase Binding, and KSR Overexpression , 1999, Molecular and Cellular Biology.

[132]  A. Wolfman,et al.  Oncogenic Ha-Ras-dependent Mitogen-activated Protein Kinase Activity Requires Signaling Through the Epidermal Growth Factor Receptor* , 1998, The Journal of Biological Chemistry.

[133]  E. Goldsmith,et al.  A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation , 1998, Current Biology.

[134]  J. Hancock,et al.  Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase* , 1998, The Journal of Biological Chemistry.

[135]  R. Hillig,et al.  Targeting RAS oncogenesis with SOS1 inhibitors. , 2022, Advances in cancer research.

[136]  C. Der,et al.  Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. , 2022, Advances in cancer research.

[137]  E. Ortiz-Sánchez,et al.  ALDH as a Stem Cell marker in solid tumors. , 2018, Current stem cell research & therapy.

[138]  C. Dai,et al.  Visualization of RAS/MAPK Signaling In Situ by the Proximity Ligation Assay (PLA). , 2017, Methods in molecular biology.

[139]  J. Shih,et al.  ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. , 2013, Cancer letters.